Regorafenib in Relapsed Glioblastoma (REGOMA)

• ClinicalTrials.gov Identifier: NCT02926222
• Recruitment Status: Completed
• First Posted: October 6, 2016
• Last Update Posted: September 9, 2022
• Sponsor: Istituto Oncologico Veneto IRCCS
• Collaborator: BAYER S.p.A. - Italia
• Information provided by (Responsible Party): Istituto Oncologico Veneto IRCCS

Study Description

Brief Summary:

This study aims to evaluate the role of Regorafenib in prolonging the overall survival of glioblastoma multiforme patients who progressed after surgery and Stupp regimen with or without bevacizumab.

Condition or disease	Intervention/treatment	Phase
Glioblastoma Multiforme	Drug: Regorafenib; Drug: Lomustine	Phase 2

Detailed Description:

The primary aim of the study is to evaluate the overall survival (OS) in the intention to treat (ITT) population. Secondary aims are to evaluate the progression free survival (PFS), safety, objective response rate (ORR), disease control rate (DCR) in the ITT population, and the evaluation of quality of life (QoL). Additional exploratory objectives include the analysis of antiangiogenic and metabolic biomarkers in tissue at first and second surgery (if performed) by the evaluation of certain metabolic features of tumors that could be involved in tumor responses to antiangiogenic drugs.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 119 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: Regorafenib in Relapsed Glioblastoma REGOMA Study Randomized, Controlled Open-label Phase II Clinical Trial
• Actual Study Start Date: November 2015
• Actual Primary Completion Date: July 2017
• Actual Study Completion Date: June 2021

Arms and Interventions

Arm	Intervention/treatment
Experimental: ARM A - Regorafenib; Patients receive REGORAFENIB 40 mg tablets once daily (160 mg/die), 3 weeks on, 1 week off, until disease progression or unacceptable toxicity.	Drug: Regorafenib; Regorafenib is formulated as tablets of 40mg for oral administration.; Other Name: Stivarga
Active Comparator: ARM B - Lomustine; Patients receive LOMUSTINE 110 mg/m2 orally on day 1, every 6 weeks (q6w), until disease progression or unacceptable toxicity.	Drug: Lomustine; Lomustine is formulated as tablets of 40mg for oral administration.; Other Name: Ceenu

Outcome Measures

Primary Outcome Measures :

1. Overall survival [ Time Frame: From the date of randomization to 18 months or to the date of death from any cause ]

Secondary Outcome Measures :

1. Progression free survival [ Time Frame: From the date of randomization to 18 months or to the date of disease progression or to the date of death, whichever occurs first ]
2. Objective response rate [ Time Frame: Approximately 36 months ]
   As percentage of patients achieving a complete response plus partial response
3. Disease control rate [ Time Frame: Approximately 36 months ]
   As percentage of patients achieving a complete response plus partial response plus stable disease
4. Toxicity (Graded according to the NCI-Common Terminology Criteria for Adverse Events) [ Time Frame: Approximately every 4 weeks through the treatment period up to 30 days after the end of treatment ]
   Graded according to the NCI-Common Terminology Criteria for Adverse Events (CTCAE) v.4

Other Outcome Measures:

1. Quality of life EORTC [ Time Frame: From the date of randomization, approximately every 3 months until the date of first documented progression or date of death from any cause, or study withdrawal, whichever came first, assessed up to 30 months. ]

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Male or female ≥ 18 years of age
• Histologically confirmed de novo glioblastoma multiforme (grade IV)
• First recurrence after adjuvant treatment (surgery followed by radiotherapy and temozolomide chemotherapy with or without bevacizumab) in patients who have not received further therapeutic interventions
• For patients not undergoing a second surgery at the time of relapse, recurrent disease must include at least one bi-dimensionally measurable contrast-enhancing lesion with clearly defined margins by MRI scan, with minimal diameters of 10 mm, visible on 2 or more axial slices 5 mm apart, based on an MRI scan done within 2 weeks prior to randomization
• Documented progression of disease as defined by RANO criteria at least 12 weeks after completion of radiotherapy, unless the recurrence is outside the radiation field or has been histologically documented

• Have adequate bone marrow function, liver function, and renal function, as measured by the following laboratory assessments conducted within 7 days prior to the initiation of study treatment:

  • Hemoglobin >9.0 g/dl
  • Absolute neutrophil count (ANC) >1500/mm3 without transfusions or granulocyte colony stimulating factor and other hematopoietic growth factors
  • Platelet count ≥100,000/μl
  • White blood cell count (WBC) >3.0 x 109/L
  • Total bilirubin <1.5 times the upper limit of normal
  • ALT and AST <3 x upper limit of normal (<5 x upper limit of normal for patients with liver involvement of their cancer and/or have bone metastasis)
  • Serum creatinine <1.5 x upper limit of normal
  • Alkaline phosphatase <2.5 x ULN (<5 x upper limit of normal for patients with liver involvement of their cancer and/or have bone metastasis)
  • PT-INR/PTT <1.5 x upper limit of normal (Patients who are being therapeutically anticoagulated with an agent such as coumadin or heparin will be allowed to participate provided that no prior evidence of underlying abnormality in these parameters exists per medical history)
  • Lipase ≤ 1.5 x the ULN
• Glomerular filtration rate ≥ 30 mL/min/1.73 m2 according to the Modified Diet in Renal Disease abbreviated formula
• Analyses of MGMT methylation status on tumoral tissue at first surgery (at own institution)
• Understand, be willing to give consent, and sign the written informed consent form (ICF) prior to undergoing any study-specific procedure
• If female and of childbearing potential, have a negative result on a pregnancy test performed a maximum of 7 days before initiation of study treatment
• If female and of childbearing potential, or if male, agree to use adequate contraception (eg, intrauterine device, oral contraceptive, or double-barrier method) based on the judgment of the investigator or a designated associate from the date on which the ICF is signed until 8 weeks after the last dose of study drug
• World Health Organization (WHO) Performance status ≤ 1 (or Karnofsky performance status (KPS) ≥70)) within 14 days prior to the initiation of study treatment
• Stable or decreasing dosage of steroids for 7 days prior to the baseline MRI scan.

• Patients may have undergone surgery for the recurrence; the histological report must document a glioblastoma recurrence. If operated:

  • at least 28 days and maximum 42 days interval from the surgery is required prior to administration of study drugs and patients should have fully recovered
  • Exclusion Criteria:
• Are taking strong cytochrome P (CYP) CYP3A4 inhibitors (eg, clarithromycin, indinavir, itraconazole, ketoconazole, nefazodone, nelfinavir, posaconazole, ritonavir, saquinavir, telithromycin, voriconazole) or strong CYP3A4 inducers (eg, carbamazepine, phenobarbital, phenytoin, rifampin, St. John's Wort)
• Radiotherapy within 12 weeks prior to the diagnosis of progression, if the lesion is in the radiation field,
• Have had systemic anticancer therapy including cytotoxic therapy, signal transduction inhibitors, immunotherapy, and/or hormonal therapy within 4 weeks prior to initiation of study treatment
• Positioning of carmustin wafers during first or second surgery
• Other active or inactive malignancy (except for carcinoma in situ of the cervix, of the prostate or basal cell carcinoma). Malignancy will be considered inactive if patients are in complete remission for at least 3 years prior to study entry
• Have had prior treatment with regorafenib or any other VEGFR-targeting kinase inhibitor
• Have had a major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to initiation of study treatment
• Are pregnant
• Are breastfeeding
• Are unable to swallow oral tablets (crushing of study treatment tablets is not allowed)
• Have congestive heart failure classified as New York Heart Association Class 2 or higher
• Have had unstable angina (angina symptoms at rest) or new-onset angina ≤ 3 months prior to screening.
• Have had a myocardial infarction < 6 months prior to initiation of study treatment
• Have cardiac arrhythmias requiring anti-arrhythmic therapy, with the exception of beta blockers or digoxin
• Have uncontrolled hypertension (systolic blood pressure [SBP] > 140 mmHg or diastolic blood pressure [DBP] > 90 mmHg) despite optimal medical management
• Have had arterial thrombotic or embolic events such as cerebrovascular accident (including transient ischemic attacks), or pulmonary embolism within 6 months prior to the initiation of study treatment
• Have an ongoing infection with severity of Grade 2 or above (NCI-CTCAE v 4.0)
• Have a known history of human immunodeficiency virus infection
• Have either active or chronic hepatitis B or C requiring treatment with antiviral therapy
• Have a history of organ allograft
• Have evidence or history of any bleeding diathesis (including mild hemophilia), irrespective of severity
• Have had a hemorrhage or a bleeding event ≥ Grade 3 (NCI-CTCAE v 4.0) within 4 weeks prior to the initiation of study treatment
• Have a non-healing wound, ulcer, or bone fracture
• Have renal failure requiring hemodialysis or peritoneal dialysis
• Have dehydration ≥ Grade 1 (NCI-CTCAE v 4.0)
• Have interstitial lung disease with ongoing signs and symptoms at the time informed consent is obtained
• Have persistent proteinuria > 3.5 g/24 hours measured by urine protein creatinine ratio from a random urine sample (Grade 3, NCI-CTCAE v 4.0)
• Have any other serious or unstable illness, or medical, psychological, or social condition, that could jeopardize the safety of the subject and/or his/her compliance with study procedures, or may interfere with the subject's participation in the study or evaluation of the study results
• Have a known hypersensitivity to any of the study drugs, study drug classes, or excipients in the formulation of the study drugs
• Have any malabsorption condition
• Recurrent disease located outside of the brain

Contacts and Locations

Locations

Italy

IRCCS "Saverio de Bellis

Castellana Grotte, BA, Italy, 70013

Ospedale di Bellaria

Bologna, BO, Italy

Azienda Ospedaliera "G.Rummo"

Benevento, BR, Italy

istituto Scientifico Romagnolo per lo Studio e Cura dei Tumori

Cesena, FC, Italy, 47014

Istituto Neurologico C. Besta IRCCS

Milano, MI, Italy, 20133

Istituto Oncologico Veneto IRCCS, Oncologia Medica 1

Padova, PD, Italy, 35128

Ospedale Santa Chiara

Pisa, PI, Italy, 56126

Azienda Ospedaliero Universitaria S. Maria della Misericordia

Udine, UD, Italy, 33100

Istituto Nazionale Tumori Regina Elena

Roma, Italy, 00144

Azienda Ospedaliera Universitaria Città della Salute e della Scienza

Torino, Italy, 10126

Sponsors and Collaborators

Istituto Oncologico Veneto IRCCS

BAYER S.p.A. - Italia

Investigators

• Principal Investigator: Vittorina Zagonel, MD; Istituto Oncologico Veneto IRCCS

More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

Lombardi G, Del Bianco P, Brandes AA, Eoli M, Ruda R, Ibrahim T, Lolli I, Rizzato S, Daniele B, Pace A, Pasqualetti F, Caccesse M, Bergo E, Magni G, De Salvo GL, Zagonel V. Patient-reported outcomes in a phase II randomised study of regorafenib compared with lomustine in patients with relapsed glioblastoma (the REGOMA trial). Eur J Cancer. 2021 Sep;155:179-190. doi: 10.1016/j.ejca.2021.06.055. Epub 2021 Aug 10.

Lombardi G, De Salvo GL, Brandes AA, Eoli M, Ruda R, Faedi M, Lolli I, Pace A, Daniele B, Pasqualetti F, Rizzato S, Bellu L, Pambuku A, Farina M, Magni G, Indraccolo S, Gardiman MP, Soffietti R, Zagonel V. Regorafenib compared with lomustine in patients with relapsed glioblastoma (REGOMA): a multicentre, open-label, randomised, controlled, phase 2 trial. Lancet Oncol. 2019 Jan;20(1):110-119. doi: 10.1016/S1470-2045(18)30675-2. Epub 2018 Dec 3.

• Responsible Party: Istituto Oncologico Veneto IRCCS
• ClinicalTrials.gov Identifier: NCT02926222
• Other Study ID Numbers: IOV-GB-1-2014 REGOMA; 2014-003722-41 ( EudraCT Number )
• First Posted: October 6, 2016
• Last Update Posted: September 9, 2022
• Last Verified: September 2022

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: Undecided

Additional relevant MeSH terms:

Glioblastoma; Astrocytoma; Glioma; Neoplasms, Neuroepithelial; Neuroectodermal Tumors; Neoplasms, Germ Cell and Embryonal; Neoplasms by Histologic Type; Neoplasms; Neoplasms, Glandular and Epithelial; Neoplasms, Nerve Tissue; Lomustine; Antineoplastic Agents, Alkylating; Alkylating Agents; Molecular Mechanisms of Pharmacological Action; Antineoplastic Agents